Amarin just rolled out a battery of promising new data for Vascepa — brace yourself for the M&A chatter to come
Amarin hasn’t stopped astonishing analysts.
Five weeks after the company offered a big thumbs-up to its 7-year REDUCE-IT cardio study of Vascepa, with more than 8,000 patients, researchers showed up at the annual science meeting of the AHA with a battery of highly positive results for a slew of secondary endpoints.
But the latest, detailed update also raised a royal ruckus over the weekend over what exactly caused the positive effect, a single significant safety data point to consider and whether the company stacked the deck in its favor with the mineral oil it used in the placebo. And that has the company’s shares in the red early Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.